Savara, Inc. (SVRA)
4.35
-0.86
(-16.51%)
USD |
NASDAQ |
Nov 20, 10:35
Savara Cash from Operations (Quarterly) : -42.46M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -42.46M |
| June 30, 2026 | -29.75M |
| March 31, 2026 | -33.05M |
| December 31, 2025 | -25.06M |
| September 30, 2025 | -22.53M |
| June 30, 2025 | -26.26M |
| March 31, 2025 | -27.19M |
| December 31, 2024 | -23.28M |
| September 30, 2024 | -22.67M |
| June 30, 2024 | -22.50M |
| March 31, 2024 | -20.64M |
| December 31, 2023 | -15.60M |
| September 30, 2023 | -13.16M |
| June 30, 2023 | -10.27M |
| March 31, 2023 | -12.03M |
| December 31, 2022 | -8.651M |
| September 30, 2022 | -8.162M |
| June 30, 2022 | -9.316M |
| March 31, 2022 | -8.425M |
| December 31, 2021 | -9.363M |
| September 30, 2021 | -8.927M |
| June 30, 2021 | -12.19M |
| March 31, 2021 | -9.597M |
| December 31, 2020 | -12.30M |
| September 30, 2020 | -6.705M |
| Date | Value |
|---|---|
| June 30, 2020 | -7.752M |
| March 31, 2020 | -13.08M |
| December 31, 2019 | -9.946M |
| September 30, 2019 | -11.41M |
| June 30, 2019 | -12.90M |
| March 31, 2019 | -10.86M |
| December 31, 2018 | -10.49M |
| September 30, 2018 | -8.762M |
| June 30, 2018 | -10.35M |
| March 31, 2018 | -9.671M |
| December 31, 2017 | -9.47M |
| September 30, 2017 | -8.249M |
| June 30, 2017 | -7.671M |
| March 31, 2017 | -2.844M |
| December 31, 2016 | -2.19M |
| September 30, 2016 | -2.865M |
| June 30, 2016 | 8.013M |
| March 31, 2016 | -11.33M |
| December 31, 2015 | -8.811M |
| September 30, 2015 | -8.256M |
| June 30, 2015 | -8.533M |
| March 31, 2015 | -7.349M |
| December 31, 2014 | -6.015M |
| September 30, 2014 | -5.368M |
| June 30, 2014 | -6.99M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 11.50M |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
| Anika Therapeutics, Inc. | 8.377M |
| Arrowhead Pharmaceuticals, Inc. | -192.40M |
| Vericel Corp. | 17.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 31.01M |
| Cash from Financing (Quarterly) | -0.385M |
| Free Cash Flow | -130.94M |
| Free Cash Flow Per Share (Quarterly) | -0.1684 |
| Free Cash Flow to Equity (Quarterly) | -42.77M |
| Free Cash Flow to Firm (Quarterly) | -42.82M |
| Free Cash Flow Yield | -14.65% |